A large trial of aspirin use in the adjuvant setting is ongoing which randomizes aspirin use to women with HER2 negative, early stage breast cancers to assess recurrence risk by aspirin use (clinicaltrials.gov #NCT02927249). This evidence concerns the gene ERBB2 and breast cancer.